BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol. 1993;120:1281-1288. [PMID: 8436594 DOI: 10.1083/jcb.120.5.1281] [Cited by in Crossref: 159] [Cited by in F6Publishing: 156] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Vijayasaradhi S, Houghton AN. Melanoma and melanocytes: pigmentation, tumor progression, and the immune response to cancer. Adv Pharmacol 1995;32:343-74. [PMID: 7748799 DOI: 10.1016/s1054-3589(08)61017-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Dubost JJ, Rolhion C, Tchirkov A, Bertrand S, Chassagne J, Dosgilbert A, Verrelle P. Interleukin-6-producing cells in a human glioblastoma cell line are not affected by ionizing radiation. J Neurooncol 2002;56:29-34. [PMID: 11949824 DOI: 10.1023/a:1014467804488] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lupetti R, Mortarini R, Panceri P, Sensi M, Anichini A. Interaction with fibronectin regulates cytokine gene expression in human melanoma cells. Int J Cancer 1996;66:110-6. [PMID: 8608953 DOI: 10.1002/(SICI)1097-0215(19960328)66:1<110::AID-IJC19>3.0.CO;2-H] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Chung TD, Yu JJ, Kong TA, Spiotto MT, Lin JM. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate 2000;42:1-7. [DOI: 10.1002/(sici)1097-0045(20000101)42:1<1::aid-pros1>3.0.co;2-y] [Cited by in Crossref: 71] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
5 Moretti S, Chiarugi A, Semplici F, Salvi A, De Giorgi V, Fabbri P, Mazzoli S. Serum imbalance of cytokines in melanoma patients. Melanoma Res 2001;11:395-9. [PMID: 11479428 DOI: 10.1097/00008390-200108000-00010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
6 Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 1994;56:853-7. [PMID: 7509778 DOI: 10.1002/ijc.2910560617] [Cited by in Crossref: 170] [Cited by in F6Publishing: 146] [Article Influence: 6.3] [Reference Citation Analysis]
7 MacDougall JR, Bani MR, Lin Y, Muschel RJ, Kerbel RS. 'Proteolytic switching': opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. Br J Cancer 1999;80:504-12. [PMID: 10408860 DOI: 10.1038/sj.bjc.6690385] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 2.4] [Reference Citation Analysis]
8 Malaguarnera L, Ferlito L, Di Mauro S, Imbesi RM, Scalia G, Malaguarnera M. Immunosenescence and cancer: a review. Arch Gerontol Geriatr 2001;32:77-93. [PMID: 11313099 DOI: 10.1016/s0167-4943(01)00087-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
9 Jones TH, Justice SK, Timperley WR, Royds JA. Effects of interleukin-1 and dexamethasone on interleukin-6 production and growth in human meningiomas. J Pathol 1997;183:460-8. [DOI: 10.1002/(sici)1096-9896(199712)183:4<460::aid-path961>3.0.co;2-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003;88:1721-6. [PMID: 12771987 DOI: 10.1038/sj.bjc.6600956] [Cited by in Crossref: 204] [Cited by in F6Publishing: 180] [Article Influence: 11.3] [Reference Citation Analysis]
11 Albino AP, Fountain JW. Oncogenes and Tumor Suppressor Genes in Cutaneous Malignant Melanoma. Photochem Photobiol 1996;63:412-8. [DOI: 10.1111/j.1751-1097.1996.tb03058.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
12 Satomi H, Wang B, Fujisawa H, Otsuka F. Interferon-beta from melanoma cells suppresses the proliferations of melanoma cells in an autocrine manner. Cytokine 2002;18:108-15. [PMID: 12096926 DOI: 10.1006/cyto.2002.1028] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
13 Voyle RB, Haines BP, Pera MF, Forrest R, Rathjen PD. Human Germ Cell Tumor Cell Lines Express Novel Leukemia Inhibitory Factor Transcripts Encoding Differentially Localized Proteins. Experimental Cell Research 1999;249:199-211. [DOI: 10.1006/excr.1999.4469] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
14 Thies A, Nugel D, Pfüller U, Moll I, Schumacher U. Influence of mistletoe lectins and cytokines induced by them on cell proliferation of human melanoma cells in vitro. Toxicology 2005;207:105-16. [PMID: 15590126 DOI: 10.1016/j.tox.2004.09.009] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
15 Zhong W, Chen W, Zhang D, Sun J, Li Y, Zhang J, Gao Y, Zhou W, Li S. CXCL12/CXCR4 axis plays pivotal roles in the organ-specific metastasis of pancreatic adenocarcinoma: A clinical study. Exp Ther Med. 2012;4:363-369. [PMID: 23181100 DOI: 10.3892/etm.2012.631] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
16 Lin Y, Chang Z, Liao Y, Chou M, Tang C. IL-6 promotes ICAM-1 expression and cell motility in human osteosarcoma. Cancer Letters 2013;328:135-43. [DOI: 10.1016/j.canlet.2012.08.029] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
17 Howell WM, Turner SJ, Theaker JM, Bateman AC. Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma. Eur J Immunogenet. 2003;30:409-414. [PMID: 14675394 DOI: 10.1111/j.1365-2370.2003.00425.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 3.4] [Reference Citation Analysis]
18 Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today. 1997;18:493-497. [PMID: 9357142 DOI: 10.1016/s0167-5699(97)01115-8] [Cited by in Crossref: 269] [Cited by in F6Publishing: 35] [Article Influence: 11.7] [Reference Citation Analysis]
19 Arzt E, Pereda MP, Castro CP, Pagotto U, Renner U, Stalla GK. Pathophysiological role of the cytokine network in the anterior pituitary gland. Front Neuroendocrinol. 1999;20:71-95. [PMID: 9882537 DOI: 10.1006/frne.1998.0176] [Cited by in Crossref: 89] [Cited by in F6Publishing: 70] [Article Influence: 4.0] [Reference Citation Analysis]
20 Dunn JH, Ellis LZ, Fujita M. Inflammasomes as molecular mediators of inflammation and cancer: Potential role in melanoma. Cancer Letters 2012;314:24-33. [DOI: 10.1016/j.canlet.2011.10.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
21 Oldford SA, Haidl ID, Howatt MA, Leiva CA, Johnston B, Marshall JS. A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. J Immunol 2010;185:7067-76. [PMID: 21041732 DOI: 10.4049/jimmunol.1001137] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 7.4] [Reference Citation Analysis]
22 Reichner JS, Mulligan JA, Spisni R, Sotomayor EA, Albina JE, Bland KI. Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells. Ann Surg Oncol 1998;5:279-86. [PMID: 9607632 DOI: 10.1007/BF02303786] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
23 Rodeck U. Growth factor independence and growth regulatory pathways in human melanoma development. Cancer Metast Rev 1993;12:219-26. [DOI: 10.1007/bf00665954] [Cited by in Crossref: 41] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
24 Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med (Berl). 2003;81:20-31. [PMID: 12545246 DOI: 10.1007/s00109-002-0397-4] [Cited by in Crossref: 147] [Cited by in F6Publishing: 130] [Article Influence: 7.7] [Reference Citation Analysis]
25 Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38:199-207. [DOI: 10.1002/(sici)1097-0045(19990215)38:3<199::aid-pros4>3.0.co;2-h] [Cited by in Crossref: 153] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
26 Kalai M, Montero-julian FA, Grötzinger J, Fontaine V, Vandenbussche P, Deschuyteneer R, Wollmer A, Brailly H, Content J. Analysis of the Human Interleukin-6/Human Interleukin-6 Receptor Binding Interface at the Amino Acid Level: Proposed Mechanism of Interaction. Blood 1997;89:1319-33. [DOI: 10.1182/blood.v89.4.1319] [Cited by in Crossref: 47] [Article Influence: 2.0] [Reference Citation Analysis]
27 Böhm M, Schulte U, Funk JO, Raghunath M, Behrmann I, Kortylewski M, Heinrich PC, Kues T, Luger TA, Schwarz T. Interleukin-6-resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity. J Invest Dermatol. 2001;117:132-140. [PMID: 11442760 DOI: 10.1046/j.0022-202x.2001.01372.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
28 Tartour E, Lee R, Fridman W. Anti-cytokines: promising tools for diagnosis and immunotherapy. Biomedicine & Pharmacotherapy 1994;48:417-24. [DOI: 10.1016/0753-3322(94)90002-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
29 Tartour E, Fridman WH. Cytokines and cancer. Int Rev Immunol. 1998;16:683-704. [PMID: 9646182 DOI: 10.3109/08830189809043014] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 1.4] [Reference Citation Analysis]
30 Gandour-edwards R, Kapadia SB, Gumerlock PH, Barnes L. Immunolocalization of interleukin-6 in salivary gland tumors. Human Pathology 1995;26:501-3. [DOI: 10.1016/0046-8177(95)90245-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
31 Fridman WH, Tartour E. Cytokines and cell regulation. Mol Aspects Med 1997;18:3-90. [PMID: 9100222 DOI: 10.1016/s0098-2997(96)00012-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Welker P, Schadendorf D, Artuc M, Grabbe J, Henz BM. Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications. Br J Cancer 2000;82:1453-8. [PMID: 10780526 DOI: 10.1054/bjoc.1999.1076] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
33 Hoejberg L, Bastholt L, Schmidt H. Interleukin-6 and melanoma. Melanoma Research 2012;22:327-33. [DOI: 10.1097/cmr.0b013e3283543d72] [Cited by in Crossref: 44] [Cited by in F6Publishing: 25] [Article Influence: 4.9] [Reference Citation Analysis]
34 Lederle W, Depner S, Schnur S, Obermueller E, Catone N, Just A, Fusenig NE, Mueller MM. IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines. Int J Cancer 2011;128:2803-14. [DOI: 10.1002/ijc.25621] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 7.1] [Reference Citation Analysis]
35 Vannier E, Dinarello C. Histamine enhances interleukin (IL)-1-induced IL-6 gene expression and protein synthesis via H2 receptors in peripheral blood mononuclear cells. Journal of Biological Chemistry 1994;269:9952-6. [DOI: 10.1016/s0021-9258(17)36975-2] [Cited by in Crossref: 29] [Article Influence: 1.1] [Reference Citation Analysis]
36 Xiao H, Chen L, Luo G, Son H, Prectoni JH, Zheng W. Effect of the cytokine levels in serum on osteosarcoma. Tumour Biol 2014;35:1023-8. [PMID: 23999825 DOI: 10.1007/s13277-013-1136-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
37 Zhao B, Cui K, Wang CL, Wang AL, Zhang B, Zhou WY, Zhao WH, Li S. The chemotactic interaction between CCL21 and its receptor, CCR7, facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis. J Hepatobiliary Pancreat Sci 2011;18:821-8. [PMID: 21594558 DOI: 10.1007/s00534-011-0395-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
38 Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta G, Zhong H, Han B, Ferris RL. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies. Cancer Metastasis Rev. 2006;25:333-356. [PMID: 17029028 DOI: 10.1007/s10555-006-9010-6] [Cited by in Crossref: 108] [Cited by in F6Publishing: 93] [Article Influence: 7.7] [Reference Citation Analysis]
39 Paglia D, Oran A, Lu C, Kerbel RS, Sauder DN, Mckenzie RC. Expression of Leukemia Inhibitory Factor and Interleukin-11 by Human Melanoma Cell Lines: LIF, IL-6, and IL-11 Are Not Coregulated. Journal of Interferon & Cytokine Research 1995;15:455-60. [DOI: 10.1089/jir.1995.15.455] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
40 Voyle RB, Rathjen PD. Regulated expression of alternate transcripts from the mouse oncostatin M gene: implications for interleukin-6 family cytokines. Cytokine 2000;12:134-41. [PMID: 10671298 DOI: 10.1006/cyto.1999.0541] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
41 Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer. 2007;110:1911-1928. [PMID: 17849470 DOI: 10.1002/cncr.22999] [Cited by in Crossref: 270] [Cited by in F6Publishing: 241] [Article Influence: 19.3] [Reference Citation Analysis]
42 Preisner F, Leimer U, Sandmann S, Zoernig I, Germann G, Koellensperger E. Impact of Human Adipose Tissue-Derived Stem Cells on Malignant Melanoma Cells in An In Vitro Co-culture Model. Stem Cell Rev Rep 2018;14:125-40. [PMID: 29064018 DOI: 10.1007/s12015-017-9772-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
43 Krasagakis K, Garbe C, Zouboulis CC, Orfanos CE. Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res 1995;139:169-82. [PMID: 7597288 DOI: 10.1007/978-3-642-78771-3_12] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 2.3] [Reference Citation Analysis]
44 Schadendorf D, Fichtner I, Makki A, Alijagic S, Küpper M, Mrowietz U, Henz BM. Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer. 1996;74:194-199. [PMID: 8688321 DOI: 10.1038/bjc.1996.337] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.1] [Reference Citation Analysis]
45 Moretti S, Pinzi C, Spallanzani A, Berti E, Chiarugi A, Mazzoli S, Fabiani M, Vallecchi C, Herlyn M. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int J Cancer 1999;84:160-8. [PMID: 10096249 DOI: 10.1002/(sici)1097-0215(19990420)84:2<160::aid-ijc12>3.0.co;2-r] [Cited by in Crossref: 63] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
46 Tyler DS, Francis GM, Frederick M, Tran AH, Ordóñz NG, Smith JL, Eton O, Ross M, Grimm EA. Interleukin-1 Production in Tumor Cells of Human Melanoma Surgical Specimens. Journal of Interferon & Cytokine Research 1995;15:331-40. [DOI: 10.1089/jir.1995.15.331] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
47 Labbozzetta M, Notarbartolo M, Poma P, Giannitrapani L, Cervello M, Montalto G, D’Alessandro N. Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma. Ann N Y Acad Sci. 2006;1089:268-275. [PMID: 17261774 DOI: 10.1196/annals.1386.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
48 Okamoto M, Hattori K, Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell linesin vitro. Int J Cancer 1997;72:149-54. [DOI: 10.1002/(sici)1097-0215(19970703)72:1<149::aid-ijc21>3.0.co;2-d] [Cited by in Crossref: 71] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
49 Karst AM, Gao K, Nelson CC, Li G. Nuclear factor kappa B subunit p50 promotes melanoma angiogenesis by upregulating interleukin-6 expression. Int J Cancer 2009;124:494-501. [DOI: 10.1002/ijc.23973] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
50 Tang CH, Chen CF, Chen WM, Fong YC. IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells. J Biol Chem 2011;286:11056-66. [PMID: 21278254 DOI: 10.1074/jbc.M110.204081] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
51 Schadendorf D, Kohlmus C, Gawlik C, Suter L, Czarnetzki BM. Mast cells in melanocytic tumours. Arch Dermatol Res 1995;287:452-6. [PMID: 7625856 DOI: 10.1007/BF00373428] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
52 Cho D, Kang H, Ma J, Kim S, Kim H, Pyun K, Choi I. IL-6 undergoes transition from in vitro autocrine growth factor to in vivo growth inhibitor of B lymphoma cells. J Biomed Sci 1997;4:201-7. [DOI: 10.1007/bf02253419] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
53 Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006;12:2563-8. [PMID: 16688802 DOI: 10.3748/wjg.v12.i16.2563] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 66] [Article Influence: 4.3] [Reference Citation Analysis]
54 Kodet O, Kučera J, Strnadová K, Dvořánková B, Štork J, Lacina L, Smetana K Jr. Cutaneous melanoma dissemination is dependent on the malignant cell properties and factors of intercellular crosstalk in the cancer microenvironment (Review). Int J Oncol 2020;57:619-30. [PMID: 32705148 DOI: 10.3892/ijo.2020.5090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Park J, Gores GJ, Patel T. Lipopolysaccharide induces cholangiocyte proliferation via an interleukin-6-mediated activation of p44/p42 mitogen-activated protein kinase. Hepatology. 1999;29:1037-1043. [PMID: 10094943 DOI: 10.1002/hep.510290423] [Cited by in Crossref: 98] [Cited by in F6Publishing: 83] [Article Influence: 4.5] [Reference Citation Analysis]
56 van Groningen JJ, Klink SL, Bloemers HP, Swart GW. Expression of tissue-type transglutaminase correlates positively with metastatic properties of human melanoma cell lines. Int J Cancer 1995;60:383-7. [PMID: 7829248 DOI: 10.1002/ijc.2910600319] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
57 Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D'alessandro N. Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 1999;85:134-44. [DOI: 10.1002/(sici)1097-0142(19990101)85:1<134::aid-cncr19>3.0.co;2-c] [Cited by in Crossref: 55] [Article Influence: 2.5] [Reference Citation Analysis]
58 Rödler S, Roth M, Nauck M, Tamm M, Block L. Ca2+-channel blockers modulate the expression of interleukin-6 and interleukin-8 genes in human vascular smooth muscle cells. Journal of Molecular and Cellular Cardiology 1995;27:2295-302. [DOI: 10.1016/s0022-2828(95)91803-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
59 Andrews B, Shariat SF, Kim J, Wheeler TM, Slawin KM, Lerner SP. PREOPERATIVE PLASMA LEVELS OF INTERLEUKIN-6 AND ITS SOLUBLE RECEPTOR PREDICT DISEASE RECURRENCE AND SURVIVAL OF PATIENTS WITH BLADDER CANCER. Journal of Urology 2002;167:1475-81. [DOI: 10.1016/s0022-5347(05)65348-7] [Cited by in Crossref: 68] [Article Influence: 3.6] [Reference Citation Analysis]
60 Groppo R, Richter JD. CPEB control of NF-kappaB nuclear localization and interleukin-6 production mediates cellular senescence. Mol Cell Biol 2011;31:2707-14. [PMID: 21536657 DOI: 10.1128/MCB.05133-11] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
61 Hodgson L, Henderson AJ, Dong C. Melanoma cell migration to type IV collagen requires activation of NF-kappaB. Oncogene 2003;22:98-108. [PMID: 12527912 DOI: 10.1038/sj.onc.1206059] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
62 Tamm M, Bihl M, Eickelberg O, Stulz P, Perruchoud AP, Roth M. Hypoxia-Induced Interleukin-6 and Interleukin-8 Production Is Mediated by Platelet-Activating Factor and Platelet-Derived Growth Factor in Primary Human Lung Cells. Am J Respir Cell Mol Biol 1998;19:653-61. [DOI: 10.1165/ajrcmb.19.4.3058] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 2.5] [Reference Citation Analysis]
63 Flørenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene. 1999;18:1023-1032. [PMID: 10023678 DOI: 10.1038/sj.onc.1202382] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 2.5] [Reference Citation Analysis]
64 Alileche A. Interleukin-2 and cancer: critical analysis of results, problems and expectations. Med Hypotheses 2003;60:202-8. [PMID: 12606236 DOI: 10.1016/s0306-9877(02)00359-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
65 Guida M, Riccobon A, Biasco G, Ravaioli A, Casamassima A, Freschi A, Palma MD, Galligioni E, Nortilli R, Chiarion-Sileni V, Picozzo J, Romanini A, Nanni O, Ridolfi R; Italian Melanoma Intergroup (IMI). Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. Melanoma Res 2006;16:317-23. [PMID: 16845327 DOI: 10.1097/01.cmr.0000200491.00841.5f] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
66 Park JI, Strock CJ, Ball DW, Nelkin BD. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol 2003;23:543-54. [PMID: 12509453 DOI: 10.1128/MCB.23.2.543-554.2003] [Cited by in Crossref: 97] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
67 Gray CP, Arosio P, Hersey P. Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells. Blood. 2002;99:3326-3334. [PMID: 11964300 DOI: 10.1182/blood.v99.9.3326] [Cited by in Crossref: 73] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
68 Sugawara H, Yasoshima M, Katayanagi K, Kono N, Watanabe Y, Harada K, Nakanuma Y. Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma. Histopathology 1998;33:145-53. [PMID: 9762547 DOI: 10.1046/j.1365-2559.1998.00445.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 2.9] [Reference Citation Analysis]
69 Bielefeldt-ohmann H, Marzo AL, Himbeck RP, Jarnicki AG, Robinson BWS, Fitzpatrick DR. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon ? immunotherapy. Cancer Immunol Immunother 1995;40:241-50. [DOI: 10.1007/bf01519898] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
70 Roth M, Nauck M, Tamm M, Perruchoud AP, Ziesche R, Block LH. Intracellular interleukin 6 mediates platelet-derived growth factor-induced proliferation of nontransformed cells. Proc Natl Acad Sci U S A 1995;92:1312-6. [PMID: 7877973 DOI: 10.1073/pnas.92.5.1312] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 2.2] [Reference Citation Analysis]
71 Stieglitz D, Lamm S, Braig S, Feuerer L, Kuphal S, Dietrich P, Arndt S, Echtenacher B, Hellerbrand C, Karrer S, Bosserhoff AK. BMP6-induced modulation of the tumor micro-milieu. Oncogene 2019;38:609-21. [PMID: 30171260 DOI: 10.1038/s41388-018-0475-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
72 Diller ML, Kudchadkar RR, Delman KA, Lawson DH, Ford ML. Exogenous IL-2 Induces FoxP3+ Th17 Cells In Vivo in Melanoma Patients. J Immunother 2016;39:355-66. [PMID: 27741090 DOI: 10.1097/CJI.0000000000000139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
73 Bjoern J, Juul Nitschke N, Zeeberg Iversen T, Schmidt H, Fode K, Svane IM. Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. Oncoimmunology 2016;5:e1100788. [PMID: 27141381 DOI: 10.1080/2162402X.2015.1100788] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
74 Mirea MA, Eckensperger S, Hengstschläger M, Mikula M. Insights into Differentiation of Melanocytes from Human Stem Cells and Their Relevance for Melanoma Treatment. Cancers (Basel) 2020;12:E2508. [PMID: 32899370 DOI: 10.3390/cancers12092508] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
75 Haines BP, Voyle RB, Rathjen PD. Intracellular and extracellular leukemia inhibitory factor proteins have different cellular activities that are mediated by distinct protein motifs. Mol Biol Cell 2000;11:1369-83. [PMID: 10749936 DOI: 10.1091/mbc.11.4.1369] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
76 Candi E, Knight RA, Spinedi A, Guerrieri P, Melino G. A possible growth factor role of IL-6 in neuroectodermal tumours. J Neurooncol 1997;31:115-22. [PMID: 9049837 DOI: 10.1023/a:1005706019048] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
77 Minichsdorfer C, Wasinger C, Sieczkowski E, Atil B, Hohenegger M. Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells. Melanoma Res 2015;25:284-94. [PMID: 26020489 DOI: 10.1097/CMR.0000000000000172] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
78 Spiotto MT, Chung TD. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 2000;42:88-98. [DOI: 10.1002/(sici)1097-0045(20000201)42:2<88::aid-pros2>3.0.co;2-p] [Cited by in Crossref: 101] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
79 Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA. 1994;91:1198-1205. [PMID: 8108387 DOI: 10.1073/pnas.91.4.1198] [Cited by in Crossref: 492] [Cited by in F6Publishing: 432] [Article Influence: 18.2] [Reference Citation Analysis]
80 Cui K, Zhao W, Wang C, Wang A, Zhang B, Zhou W, Yu J, Sun Z, Li S. The CXCR4-CXCL12 pathway facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis. J Surg Res. 2011;171:143-150. [PMID: 20462600 DOI: 10.1016/j.jss.2010.03.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
81 Fonsatti E, Maio M, Altomonte M, Hersey P. Biology and Clinical Applications of CD40 in Cancer Treatment. Seminars in Oncology 2010;37:517-23. [DOI: 10.1053/j.seminoncol.2010.09.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
82 Favaro D, Santarosa M, Quaia M, Galligioni E. Interleukin-6 and soluble intercellular adhesion molecule-1 in renal cancer patients and cultured renal cancer cells. Urol Oncol 1997;3:51-8. [PMID: 21227060 DOI: 10.1016/s1078-1439(97)00036-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
83 Lázár-molnár E, Hegyesi H, Tóth S, Falus A. AUTOCRINE AND PARACRINE REGULATION BY CYTOKINES AND GROWTH FACTORS IN MELANOMA. Cytokine 2000;12:547-54. [DOI: 10.1006/cyto.1999.0614] [Cited by in Crossref: 276] [Cited by in F6Publishing: 240] [Article Influence: 13.1] [Reference Citation Analysis]
84 Chuang JY, Huang YL, Yen WL, Chiang IP, Tsai MH, Tang CH. Syk/JNK/AP-1 signaling pathway mediates interleukin-6-promoted cell migration in oral squamous cell carcinoma. Int J Mol Sci 2014;15:545-59. [PMID: 24398980 DOI: 10.3390/ijms15010545] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
85 Lewko WM, Oldham RK. Cytokines. In: Oldham RK, Dillman RO, editors. Principles of Cancer Biotherapy. Dordrecht: Springer Netherlands; 2009. pp. 155-276. [DOI: 10.1007/978-90-481-2289-9_8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
86 Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST. Mast cells and cutaneous malignancies. Mod Pathol 2006;19:149-59. [DOI: 10.1038/modpathol.3800474] [Cited by in Crossref: 104] [Cited by in F6Publishing: 97] [Article Influence: 6.5] [Reference Citation Analysis]
87 Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999;41:127-33. [PMID: 10477909 DOI: 10.1002/(sici)1097-0045(19991001)41:2<127::aid-pros7>3.0.co;2-h] [Cited by in Crossref: 195] [Cited by in F6Publishing: 57] [Article Influence: 8.9] [Reference Citation Analysis]
88 Liu F. Galectins: A New Family of Regulators of Inflammation. Clinical Immunology 2000;97:79-88. [DOI: 10.1006/clim.2000.4912] [Cited by in Crossref: 133] [Cited by in F6Publishing: 125] [Article Influence: 6.3] [Reference Citation Analysis]
89 Rachkovsky M, Sodi S, Chakraborty A, Avissar Y, Bolognia J, McNiff JM, Platt J, Bermudes D, Pawelek J. Melanoma x macrophage hybrids with enhanced metastatic potential. Clin Exp Metastasis. 1998;16:299-312. [PMID: 9626809 DOI: 10.1023/a:1006557228604] [Cited by in Crossref: 85] [Cited by in F6Publishing: 46] [Article Influence: 3.7] [Reference Citation Analysis]
90 Bősze S, Hudecz F, Igaz P, Ortutay Z, Csík G, Falus A, Tóth S. Interleukin-6 N-Terminal Peptides Modulate the Expression of junB Protooncogene and the Production of Fibrinogen in HepG2 Cells. Biological Chemistry 2003;384. [DOI: 10.1515/bc.2003.047] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
91 Dorronsoro A, Lang V, Ferrin I, Fernández-Rueda J, Zabaleta L, Pérez-Ruiz E, Sepúlveda P, Trigueros C. Intracellular role of IL-6 in mesenchymal stromal cell immunosuppression and proliferation. Sci Rep 2020;10:21853. [PMID: 33318571 DOI: 10.1038/s41598-020-78864-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
92 Khoo NKS, Bechberger JF, Shepherd T, Bond SL, Mccrae KR, Hamilton GS, Lala PK. SV40 Tag transformation of the normal invasive trophoblast results in a premalignant phenotype. I. Mechanisms responsible for hyperinvasivess and resistance to anti-invasive action of TGFβ. Int J Cancer 1998;77:429-39. [DOI: 10.1002/(sici)1097-0215(19980729)77:3<429::aid-ijc20>3.0.co;2-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
93 Herlyn M, Shih IM. Interactions of melanocytes and melanoma cells with the microenvironment. Pigment Cell Res 1994;7:81-8. [PMID: 8066024 DOI: 10.1111/j.1600-0749.1994.tb00025.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.2] [Reference Citation Analysis]
94 Price JE. Analyzing the metastatic phenotype. J Cell Biochem 1994;56:16-22. [PMID: 7806587 DOI: 10.1002/jcb.240560105] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
95 Fontanini G, Campani D, Roncella M, Cecchetti D, Calvo S, Toniolo A, Basolo F. Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma. Br J Cancer 1999;80:579-84. [PMID: 10408869 DOI: 10.1038/sj.bjc.6690394] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
96 Richards CD. Interleukin-6. Cytokines. Elsevier; 1998. pp. 87-108. [DOI: 10.1016/b978-012498340-3/50007-5] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
97 Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology. 2013;58:158-170. [PMID: 23389848 DOI: 10.1002/hep.26305] [Cited by in Crossref: 195] [Cited by in F6Publishing: 182] [Article Influence: 24.4] [Reference Citation Analysis]
98 Holzer TR, Fulford AD, Nedderman DM, Umberger TS, Hozak RR, Joshi A, Melemed SA, Benjamin LE, Plowman GD, Schade AE, Ackermann BL, Konrad RJ, Nasir A. Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung. PLoS One 2013;8:e80292. [PMID: 24244672 DOI: 10.1371/journal.pone.0080292] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
99 Kučera J, Strnadová K, Dvořánková B, Lacina L, Krajsová I, Štork J, Kovářová H, Skalníková HK, Vodička P, Motlík J, Dundr P, Smetana K Jr, Kodet O. Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: Pilot study. Oncol Rep 2019;42:1793-804. [PMID: 31545456 DOI: 10.3892/or.2019.7319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
100 Khare VK, Albino AP, Reed JA. The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions. J Cutan Pathol 1998;25:2-10. [PMID: 9508337 DOI: 10.1111/j.1600-0560.1998.tb01682.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
101 Jones TH. Interleukin-6 an endocrine cytokine. Clin Endocrinol 1994;40:703-13. [DOI: 10.1111/j.1365-2265.1994.tb02502.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 1.9] [Reference Citation Analysis]
102 Abdul Rahim SN, Ho GY, Coward JI. The role of interleukin-6 in malignant mesothelioma. Transl Lung Cancer Res 2015;4:55-66. [PMID: 25806346 DOI: 10.3978/j.issn.2218-6751.2014.07.01] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
103 Sakamoto T, Liu Z, Murase N, Ezure T, Yokomuro S, Poli V, Demetris AJ. Mitosis and apoptosis in the liver of interleukin-6-deficient mice after partial hepatectomy. Hepatology 1999;29:403-11. [DOI: 10.1002/hep.510290244] [Cited by in Crossref: 191] [Cited by in F6Publishing: 174] [Article Influence: 8.7] [Reference Citation Analysis]
104 Newman MJ. Transforming growth factor beta and the cell surface in tumor progression. Cancer Metast Rev 1993;12:239-54. [DOI: 10.1007/bf00665956] [Cited by in Crossref: 33] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
105 Hutchings G, Janowicz K, Moncrieff L, Dompe C, Strauss E, Kocherova I, Nawrocki MJ, Kruszyna Ł, Wąsiatycz G, Antosik P, Shibli JA, Mozdziak P, Perek B, Krasiński Z, Kempisty B, Nowicki M. The Proliferation and Differentiation of Adipose-Derived Stem Cells in Neovascularization and Angiogenesis. Int J Mol Sci 2020;21:E3790. [PMID: 32471255 DOI: 10.3390/ijms21113790] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
106 Molnár EL, Hegyesi H, Tóth S, Darvas Z, László V, Szalai C, Falus A. Biosynthesis of interleukin-6, an autocrine growth factor for melanoma, is regulated by melanoma-derived histamine. Seminars in Cancer Biology 2000;10:25-8. [DOI: 10.1006/scbi.2000.0304] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
107 Bihl M, Tamm M, Nauck M, Wieland H, Perruchoud AP, Roth M. Proliferation of Human Non–Small-Cell Lung Cancer Cell Lines: Role of Interleukin-6. Am J Respir Cell Mol Biol 1998;19:606-12. [DOI: 10.1165/ajrcmb.19.4.3247] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 1.7] [Reference Citation Analysis]
108 D'Hellencourt CL, Diaw L, Cornillet P, Guenounou M. Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline. Int J Immunopharmacol 1996;18:739-48. [PMID: 9172017 DOI: 10.1016/s0192-0561(97)85556-7] [Cited by in Crossref: 74] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
109 Martínez-Escribano JA, Campillo JA, Piñero A, Frías JF, Sánchez-Pedreño P, Corbalán R, Minguela A, Rocío Alvarez M. [Prospective study of the levels of serum cytokines in patients with melanoma: prognostic value]. Actas Dermosifiliogr 2005;96:83-91. [PMID: 16476342 DOI: 10.1016/s0001-7310(05)73043-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Sosonkina N, Starenki D, Park JI. The Role of STAT3 in Thyroid Cancer. Cancers (Basel) 2014;6:526-44. [PMID: 24662939 DOI: 10.3390/cancers6010526] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
111 Wouters J, Stas M, Govaere O, Van den Eynde K, Vankelecom H, van den Oord JJ. Gene expression changes in melanoma metastases in response to high-dose chemotherapy during isolated limb perfusion. Pigment Cell Melanoma Res 2012;25:454-65. [PMID: 22486811 DOI: 10.1111/j.1755-148X.2012.01004.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
112 Takahashi Y, Kaneda H, Takasuka N, Hattori K, Nishikawa M, Watanabe Y, Takakura Y. Enhancement of antiproliferative activity of interferons by RNA interference-mediated silencing of SOCS gene expression in tumor cells. Cancer Sci 2008;99:1650-5. [PMID: 18754879 DOI: 10.1111/j.1349-7006.2008.00850.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
113 Tang CH, Chuang JY, Fong YC, Maa MC, Way TD, Hung CH. Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-kappaB pathways and promotes osteoclastogenesis in human oral cancer cells. Carcinogenesis 2008;29:1483-92. [PMID: 18310089 DOI: 10.1093/carcin/bgn045] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 4.7] [Reference Citation Analysis]
114 Krüger-Krasagakes S, Krasagakis K, Garbe C, Diamantstein T. Production of cytokines by human melanoma cells and melanocytes. Recent Results Cancer Res 1995;139:155-68. [PMID: 7597287 DOI: 10.1007/978-3-642-78771-3_11] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.0] [Reference Citation Analysis]
115 Plaisance S, Vanden Berghe W, Boone E, Fiers W, Haegeman G. Recombination signal sequence binding protein Jkappa is constitutively bound to the NF-kappaB site of the interleukin-6 promoter and acts as a negative regulatory factor. Mol Cell Biol 1997;17:3733-43. [PMID: 9199307 DOI: 10.1128/MCB.17.7.3733] [Cited by in Crossref: 118] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
116 Pereda M, Goldberg V, Chervín A, Carrizo G, Molina A, Andrada J, Sauer J, Renner U, Stalla G, Arzt E. Interleukin-2 (IL-2) and IL-6 regulate c-fos protooncogene expression in human pituitary adenoma explants. Molecular and Cellular Endocrinology 1996;124:33-42. [DOI: 10.1016/s0303-7207(96)03924-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
117 Neagu M, Constantin C, Tanase C. Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma. Expert Rev Mol Diagn 2010;10:897-919. [PMID: 20964610 DOI: 10.1586/erm.10.81] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
118 Ke L, Xiang Y, Xia W, Yang J, Yu Y, Ye Y, Liang H, Guo X, Lv X. A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pre-treatment interleukin 6 and clinical stage. Clin Immunol 2016;164:45-51. [PMID: 26780676 DOI: 10.1016/j.clim.2016.01.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
119 Silletti S, Paku S, Raz A. Tumor cell motility and metastasis: Autocrine motility factor as an example of ecto/exoenzyme cytokines. Pathol Oncol Res 1997;3:230-54. [DOI: 10.1007/bf02899927] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
120 Arzt E, Pereda MP, Costas M, Sauer J, Renner U, Holsboer F, Stalla GK. Cytokine Expression and Molecular Mechanisms of Their Auto/Paracrine Regulation of Anterior Pituitary Function and Growth. Annals of the New York Academy of Sciences 1998;840:525-31. [DOI: 10.1111/j.1749-6632.1998.tb09591.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
121 Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, Montero F, Joyeux I, Pouillart P, Fridman WH. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994;69:911-3. [PMID: 8180022 DOI: 10.1038/bjc.1994.175] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 3.2] [Reference Citation Analysis]
122 Deichmann M, Kahle B, Moser K, Wacker J, Wüst K. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 2004;91:699-702. [PMID: 15280926 DOI: 10.1038/sj.bjc.6602043] [Cited by in Crossref: 53] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
123 Li Z, Metze D, Nashan D, Müller-Tidow C, Serve HL, Poremba C, Luger TA, Böhm M. Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol 2004;123:737-45. [PMID: 15373779 DOI: 10.1111/j.0022-202X.2004.23408.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
124 Rak JW, Hegmann EJ, Lu C, Kerbel RS. Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. J Cell Physiol 1994;159:245-55. [PMID: 8163565 DOI: 10.1002/jcp.1041590208] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 1.3] [Reference Citation Analysis]
125 Oka M, Iizuka N, Yamamoto K, Gondo T, Abe T, Hazama S, Akitomi Y, Koishihara Y, Ohsugi Y, Ooba Y, Ishihara T, Suzuki T. The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 1996;16:1001-6. [PMID: 8974001 DOI: 10.1089/jir.1996.16.1001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.3] [Reference Citation Analysis]
126 Ali SA, Kaur G, Kaushik JK, Malakar D, Mohanty AK, Kumar S. Examination of pathways involved in leukemia inhibitory factor (LIF)-induced cell growth arrest using label-free proteomics approach. Journal of Proteomics 2017;168:37-52. [DOI: 10.1016/j.jprot.2017.07.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
127 Tzeng HE, Tsai CH, Chang ZL, Su CM, Wang SW, Hwang WL, Tang CH. Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma. Biochem Pharmacol. 2013;85:531-540. [PMID: 23219526 DOI: 10.1016/j.bcp.2012.11.021] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 8.2] [Reference Citation Analysis]
128 Juillerat-jeanneret L, Fioroni P, Leuenberger P. Modulation of Secretion of Interleukin-6 in Brain-Derived Microvascular Endothelial Cells. Endothelium 2009;3:31-7. [DOI: 10.3109/10623329509024656] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
129 Schwabe M, Brini AT, Bosco MC, Rubboli F, Egawa M, Zhao J, Princler GL, Kung HF. Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains. J Clin Invest 1994;94:2317-25. [PMID: 7989587 DOI: 10.1172/JCI117596] [Cited by in Crossref: 42] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
130 Reed JA, Mcnutt NS, Bogdany JK, Albino AP. Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression. Journal of Cutaneous Pathology 1996;23:495-505. [DOI: 10.1111/j.1600-0560.1996.tb01441.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
131 Lázár-Molnár E, Hegyesi H, Pállinger E, Kovács P, Tóth S, Fitzsimons C, Cricco G, Martin G, Bergoc R, Darvas Z, Rivera ES, Falus A. Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin-6. Eur J Clin Invest 2002;32:743-9. [PMID: 12406022 DOI: 10.1046/j.1365-2362.2002.01020.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
132 Matsumoto K, Fujii H, Michalopoulos G, Fung JJ, Demetris AJ. Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology. 1994;20:376-382. [PMID: 8045498 DOI: 10.1002/hep.1840200217] [Cited by in Crossref: 101] [Cited by in F6Publishing: 52] [Article Influence: 3.7] [Reference Citation Analysis]
133 Olsnes S, Klingenberg O, Wie˛dłocha A. Transport of Exogenous Growth Factors and Cytokines to the Cytosol and to the Nucleus. Physiological Reviews 2003;83:163-82. [DOI: 10.1152/physrev.00021.2002] [Cited by in Crossref: 90] [Cited by in F6Publishing: 81] [Article Influence: 5.0] [Reference Citation Analysis]
134 Steube KG, Meyer C, Drexler HG. Secretion of functional hematopoietic growth factors by human carcinoma cell lines. Int J Cancer 1998;78:120-4. [PMID: 9724103 DOI: 10.1002/(sici)1097-0215(19980925)78:1<120::aid-ijc19>3.0.co;2-f] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
135 Cervello M, Notarbartolo M, Landino M, Cusimano A, Virruso L, Montalto G, D'alessandro N. Downregulation of wild-type β-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: a possible role in the growth-regulatory effects of the cytokine? European Journal of Cancer 2001;37:512-9. [DOI: 10.1016/s0959-8049(00)00421-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
136 Ardestani SK, Inserra P, Solkoff D, Watson RR. The Role of Cytokines and Chemokines on Tumor Progression: A Review. Cancer Detect Prev 1999;23:215-25. [DOI: 10.1046/j.1525-1500.1999.99021.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
137 Far ME, Fouda M, Yahya R, El Baz H. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin’s lymphoma. J Physiol Biochem 2004;60:253-8. [DOI: 10.1007/bf03167070] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
138 Abdul M, Hoosein N. Differences in the expression and effects of interleukin-1 and -2 on androgen-sensitive and -insensitive human prostate cancer cell lines. Cancer Letters 2000;149:37-42. [DOI: 10.1016/s0304-3835(99)00341-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
139 Yan BY, Garcet S, Gulati N, Kiecker F, Fuentes-Duculan J, Gilleaudeau P, Sullivan-Whalen M, Shemer A, Mitsui H, Krueger JG. Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin. Exp Dermatol 2019;28:35-44. [PMID: 30326165 DOI: 10.1111/exd.13805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
140 Moran DM, Mattocks MA, Cahill PA, Koniaris LG, McKillop IH. Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway. J Surg Res 2008;147:23-33. [PMID: 17574577 DOI: 10.1016/j.jss.2007.04.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
141 Kleeberg UR, Suciu S, Bröcker EB, Ruiter DJ, Chartier C, Liénard D, Marsden J, Schadendorf D, Eggermont AM; EORTC Melanoma Group in cooperation with the German Cancer Society (DKG). Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004;40:390-402. [PMID: 14746858 DOI: 10.1016/j.ejca.2003.07.004] [Cited by in Crossref: 161] [Cited by in F6Publishing: 96] [Article Influence: 9.5] [Reference Citation Analysis]
142 Phillips TM, Smith P. Analysis of intracellular regulatory proteins by immunoaffinity capillary electrophoresis coupled with laser-induced fluorescence detection. Biomed Chromatogr 2003;17:182-7. [DOI: 10.1002/bmc.240] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
143 Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene. 2006;25:6170-6175. [PMID: 17028596 DOI: 10.1038/sj.onc.1209911] [Cited by in Crossref: 233] [Cited by in F6Publishing: 221] [Article Influence: 15.5] [Reference Citation Analysis]
144 Hoejberg L, Bastholt L, Johansen JS, Christensen IJ, Gehl J, Schmidt H. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Research 2012;22:287-93. [DOI: 10.1097/cmr.0b013e3283550aa5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
145 Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol. 2006;12:2563-2568. [PMID: 16688802 DOI: 10.3748/wjg.v12.i16] [Reference Citation Analysis]
146 Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 2005;105:1383-1395. [PMID: 15471951 DOI: 10.1182/blood-2004-07-2909] [Cited by in Crossref: 242] [Cited by in F6Publishing: 189] [Article Influence: 14.2] [Reference Citation Analysis]
147 Reichle A, Vogt T, Coras B, Terheyden P, Neuber K, Trefzer U, Schultz E, Berand A, Bröcker EB, Landthaler M, Andreesen R. Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res 2007;17:360-4. [PMID: 17992118 DOI: 10.1097/CMR.0b013e3282f1d2c8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
148 Diaz M, Abdul M, Hoosein N. Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2. Prostate 1998;36:32-6. [DOI: 10.1002/(sici)1097-0045(1998)8+<32::aid-pros6>3.0.co;2-i] [Cited by in Crossref: 35] [Article Influence: 1.5] [Reference Citation Analysis]
149 Heudobler D, Lüke F, Vogelhuber M, Klobuch S, Pukrop T, Herr W, Gerner C, Pantziarka P, Ghibelli L, Reichle A. Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue-Going Beyond Apoptosis Induction. Front Oncol 2019;9:1408. [PMID: 31921665 DOI: 10.3389/fonc.2019.01408] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
150 Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, Dughera L, Robecchi A, Pirisi M, Emanuelli G. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 2006;55:684-98. [DOI: 10.1007/s00262-005-0047-0] [Cited by in Crossref: 136] [Cited by in F6Publishing: 125] [Article Influence: 8.5] [Reference Citation Analysis]
151 von Felbert V, Córdoba F, Weissenberger J, Vallan C, Kato M, Nakashima I, Braathen LR, Weis J. Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma. Am J Pathol 2005;166:831-41. [PMID: 15743795 DOI: 10.1016/S0002-9440(10)62304-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
152 Ma L, Calvo F. Recent status of the antisense oligonucleotide approaches in oncology. Fundamental & Clinical Pharmacology 1996;10:97-115. [DOI: 10.1111/j.1472-8206.1996.tb00153.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
153 Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003;103:642-646. [PMID: 12494472 DOI: 10.1002/ijc.10833] [Cited by in Crossref: 261] [Cited by in F6Publishing: 238] [Article Influence: 14.5] [Reference Citation Analysis]
154 Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008;133:1019-1031. [PMID: 18555778 DOI: 10.1016/j.cell.2008.03.039] [Cited by in Crossref: 1138] [Cited by in F6Publishing: 1070] [Article Influence: 87.5] [Reference Citation Analysis]
155 Quaglino A, Schere-Levy C, Romorini L, Meiss RP, Kordon EC. Mouse mammary tumors display Stat3 activation dependent on leukemia inhibitory factor signaling. Breast Cancer Res 2007;9:R69. [PMID: 17925034 DOI: 10.1186/bcr1777] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
156 Hoosein N, Abdul M, Mccabe R, Gero E, Deftos L, Banks M, Hodges S, Finn L, Logothetis C. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations 1995;1:246-51. [DOI: 10.1016/1078-1439(96)00012-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]